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Abstract
Background aims. Autologous macrophage therapy represents a potentially significant therapeutic advance for the treat-
ment of severe progressive liver cirrhosis. Administration of macrophages has been shown to reduce inflammation and drive
fibrotic scar breakdown and tissue repair in relevant models.This therapeutic approach is being assessed for safety and fea-
sibility in a first-in-human trial (MAcrophagesTherapy for liver CirrHosis [MATCH] trial). Methods. We outline the development
and validation phases of GMP production.This includes use of the CliniMACS Prodigy cell sorting system to isolate CD14+
cells; optimizing macrophage culture conditions, assessing cellular identity, product purity, functional capability and deter-
mining the stability of the final cell product. Results. The GMP-compliant macrophage products have a high level of purity
and viability, and have a consistent phenotypic profile, expressing high levels of mature macrophage markers 25F9 and CD206
and low levels of CCR2.The macrophages demonstrate effective phagocytic capacity, are constitutively oriented to an anti-
inflammatory profile and remain responsive to cytokine and TLR stimulation. The process validation shows that the cell
product in excipient is remarkably robust, consistently passing the viability and phenotypic release criteria up to 48 hours
after harvest. Conclusions. This is the first report of validation of a large-scale, fully Good Manufacturing Practice–
compliant, autologous macrophage cell therapy product for the potential treatment of cirrhosis. Phenotypic and functional
assays confirm that these cells remain functionally viable for up to 48 h, allowing significant flexibility in administration to
patients.
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Introduction
Liver cirrhosis is a major health problem in theWestern
world and a leading cause of mortality in the United
Kingdom [1]. The disease is associated with a high
level of morbidity due to the progressive tissue damage,
fibrotic scarring and loss of liver function, and the only
curative option for end-stage disease is liver trans-
plantation. However, donor organ availability cannot
meet demand, and often patients with end-stage liver
disease are not eligible for transplantation.Those who
do receive transplantation require lifelong immuno-
suppression with the increased health risks involved.
Alternative therapies that prevent or delay the tran-
sition to terminal decompensated stages are urgently
required [2].
The pathology of liver cirrhosis can be driven by
numerous causative agents, including high alcohol con-
sumption, obesity,metabolic disorders, viral infections
or autoimmune disease, resulting in the progressive
loss of healthy hepatocyte tissue and liver architec-
ture, replaced bymyofibroblast-derived fibrotic scarring
[3,4]. It has been increasingly recognized that if the
agents driving liver damage are removed (e.g., alcohol,
viruses), then liver fibrosis can be at least partially re-
versible, enabling liver regeneration to occur [5].Animal
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models of liver regeneration after experimental liver
damage have shown that macrophages play a key role
in the control and repair of fibrotic liver disease [6].
The macrophage compartment of the liver is complex
and dynamic and can be significantly modulated by
disease [7]. Resident Kuppfer cells and recruited
hematopoietic-derived macrophages have distinct but
overlapping functions;however, it is clear that liver repair
can be therapeutically reproduced by administration
of monocyte-derived macrophages but not undiffer-
entiated bone marrow cells or monocytes [8]. Indeed,
inflammatory monocytes can contribute significantly
to pathology [9]. Macrophage therapy can resolve
carbon tetrachloride (CCL4)-mediated liver damage
via decrease in myofibroblast levels and increased anti-
inflammatory cytokine production [8]. Furthermore,
macrophage-mediatedmatrix metalloprotease (MMP)
release and phagocytosis is essential for fibrotic scar
resolution [10].Macrophages are also able to stimulate
hepatic progenitor cells to proliferate and differentiate
and replenish lost hepatocytes through Wnt and
TWEAK signalling [11,12]. Adoptive macrophage
therapy therefore offers a significant potential treatment
strategy for patients with cirrhotic liver disease to
promote resolution of fibrosis and stimulate resolution.
A number of studies have outlined GMP-compliant
protocols for the generation of adoptive cell thera-
pies using leukocytes including dendritic cells [13–15]
natural killer cells [16] or cytotoxicT cells [17,18] inter
alia.These studies largely harness the immune func-
tion of these cells.To date, few studies or trials have
used macrophages for clinical cell therapy, focusing
on either lung cancer [19] or bladder cancer [20,21].
One study of acute spinal cord injury involved use of
autologous blood-derived macrophages [22], but this
product was small scale (<2 million cells).
We have recently demonstrated that CD14+ mono-
cytes, collected by leukapheresis from cirrhotic donors,
can be manufactured in a scalable manner into pro-
resolution phenotype macrophages [23]. We are
currently undertaking a first-in-human phase 0/1 safety
and feasibility study to generate autologous CD14+ cell–
derived macrophages under Good Manufacturing
Practice (GMP) for re-infusion into cirrhotic pa-
tients (MAcrophage Therapy for liver CirrHosis
[MATCH] trial) [24].
The MATCH trial requires the development of a
consistent, well-characterized, autologous macro-
phage cell product in doses of multiples of 108 cells.
Here, we outline the development and validation for
manufacturing of the MATCH product, including
testing of GMP-grade media and growth factors for
efficacy, analysis of cellular identity by multi-parameter
flow cytometry, quantitative assessment of monocyte
selection and macrophage purity and determination
of a panel of markers which form the Release Criteria
for the cell product. In addition, we examined the
effects of monocyte cryopreservation on deriving mac-
rophages for therapeutic use. Functional assays were
conducted to quantify the phagocytic capacity of mac-
rophages and their capacity for further polarization.
This represents the first report of large-scale GMP-
compliant macrophage manufacture and validation for
first-in-human cell therapy of advanced liver cirrhosis.
Methods
Ethics and governance
Donor buffy coats as a source of healthy donor mono-
cytes were provided by Scottish National Blood
Transfusion Service (SNBTS) Blood Donor Centre,
Edinburgh, United Kingdom, under SNBTS Sample
Governance 13-12 and 14-02. For full-scale GMP
process optimization and validation, peripheral blood
mononuclear cells (PBMCs)were collected by
leukapheresis in the SNBTS Clinical Apheresis Unit,
Royal Infirmary of Edinburgh. Ethical approval was
granted from the South East Scotland Research Ethics
Committee 02. Informed consent for apheresis dona-
tion was obtained in accordance with the Helsinki
Declaration.
Cell preparation
CD14 selection from PBMCs: PBMCs were sepa-
rated from normal donor buffy coats by density
centrifugation using Histopaque 1077 (Sigma). After
washing, CD14+ monocytes were isolated from the
mononuclear cell fraction using CliniMACS GMP-
grade CD14 microbeads and LS separation magnetic
columns (Miltenyi Biotec). Briefly, cells were re-
suspended to appropriate concentration in PEA buffer
(phosphate-buffered saline [PBS] plus 2.5 mmol/L
ethylenediaminetetraacetic acid [EDTA] and human
serum albumin [0.5% final volume of Alburex 20%,
Octopharma]), incubated with CliniMACS CD14
beads per manufacturer’s instructions, then washed
and passed through a magnetized LS column. After
washing, the purified monocytes were eluted from the
demagnetized column, washed and re-suspended in
relevant medium for culture.
Isolation of CD14+ cells from leukapheresis:
PBMCs were collected by leukapheresis from cirrhotic
donors who gave informed consent to participate in
the study. Eligibility criteria were age range of 18 to
75 years, and cirrhosis was defined by any one of the
following: previous liver biopsy confirming histologi-
cal features of cirrhosis, transient elastography
(Fibroscan) > 18 kPa and/or clinical and radiologi-
cal features that in the opinion of the clinical lead
correlated with a diagnosis of cirrhosis. Exclusion
criteria were viral hepatitis, average alcohol ingestion
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>21 units/week (male) or >14 units/week (female),
ascites not well controlled with diuretic therapy in
the preceding 3 months, encephalopathy requiring
hospitalisation for treatment in the previous 3 months,
portal hypertensive bleeding in the preceding 3 months,
hepatocellular carcinoma, other cancer within the pre-
vious 5 years, previous liver transplant or currently on
the waiting list, the presence of a clinically relevant
acute illness that might compromise safe presenta-
tion and pregnancy and/or breast-feeding.
Leukapheresis of peripheral blood for mono-
nuclear cells (MNCs) was carried out using an Optia
apheresis system by sterile collection. A standard col-
lection program for MNC was used, processing 2.5
blood volumes.
Isolation of CD14 cells was carried out using
a GMP-compliant functionally closed system
(CliniMACS Prodigy system,Miltenyi Biotec). Briefly,
the leukapheresis product was sampled for cell count
and an aliquot taken for pre-separation flow cytometry.
The percentage of monocytes (CD14+) and absolute
cell number were determined, and, if required, the
volume was adjusted to meet the required criteria
for selection (≤20 × 109 total white blood cells; <400
× 106 white blood cells/mL; ≤3.5 × 109 CD14 cells,
volume 50–300 mL). CD14 cell isolation and sepa-
ration was carried out using the CliniMACS Prodigy
with CliniMACS CD14 microbeads (medical device
class III), TS510 tubing set and LP-14 program. At
the end of the process, the selected CD14+ positive
monocytes were washed in PBS/EDTA buffer
(CliniMACS buffer, Miltenyi) containing pharma-
ceutical grade 0.5% human albumin (Alburex), then
re-suspended inTexMACS (or comparator) medium
for culture.
Cell count and purity
Cell counts of total MNCs and isolated monocyte
fractions were performed using a Sysmex XP-300
automated analyzer (Sysmex). Assessment of macro-
phage numbers was carried out by flow cytometry with
TruCount tubes (Becton Dickinson) to determine
absolute cell number, as the Sysmex consistently un-
derestimated the number of macrophages.The purity
of the separation was assessed using flow cytometry
(FACSCanto II, BD Biosciences) with a panel of an-
tibodies against human leukocytes (CD45-VioBlue,
CD15-FITC, CD14-PE, CD16-APC), and product
quality was assessed by determining the amount of neu-
trophil contamination (CD45int, CD15pos).
Cell culture—development of cultures with healthy
donor samples
Optimal culture medium for macrophage differentiation
was investigated, and three candidates were tested using
buffy coat monocytes; Dulbecco’s Modified Eagle’s
Medium (DMEM; LifeTechnologies) supplemented
with 5% AB serum (SNBTS), plus two chemically
defined serum-free culture media, AIM-V (Thermo
Fisher) and TexMACS (Miltenyi). The experiments
were carried out with buffy coat monocytes cultured
in each medium for 7 days in a humidified atmosphere
at 37°C and 5% CO2 with 100 ng/mL premium grade
Macrophage Colony Stimulating Factor (M-CSF,
Miltenyi). Cells were seeded at a density of 1.8 × 107
cells/well in 4 mL medium in six-well tissue culture
plates and re-fed at days 3–4.The best response was
seen withTexMACS and this was used for all subse-
quent experiments (see Results section). A GMP-
compliant M-CSF from R&D Systems was tested at
100 ng/mL compared with the research grade M-CSF
used in the previous study [23] and was found to be
comparable to the premium grade M-CSF previ-
ously used (see Results).The GMP-grade M-CSF was
subsequently used in all further experiments with buffy
coats. A comparison was also made of deriving mac-
rophages from fresh and frozen/thawed monocytes (see
Results section). Monocytes were isolated from buffy
coats, then an aliquot was frozen in cryopreservation
medium (Cryostor CS10, Sigma) and the remainder
was cultured fresh. The frozen aliquot was thawed
several days later and cultured as before. The mac-
rophage yield and surface phenotype was assessed by
counting and flow cytometry (see “Flow cytometry
characterization” section).
Full-scale process validation with patient samples
Monocytes cultured from leukapheresis from Prodigy
isolation were cultured at 2 × 106 monocytes per cm2
and per mL in culture bags (MACS GMP differenti-
ation bags, Miltenyi) with GMP-grade TexMACS
(Miltenyi) and 100 ng/mLM-CSF.Monocytes were cul-
tured with 100 ng/mL GMP-compliant recombinant
human M-CSF (R&D Systems). Cells were cultured
in a humidified atmosphere at 37°C, with 5% CO2 for
7 days.A 50% volume media replenishment was carried
out twice during culture (days 2 and 4) with 50% of
the culture medium removed, then fed with fresh
medium supplemented with 200 ng/mL M-CSF (to
restore a final concentration of 100 ng/mL).
Cell harvesting
For normal donor-derived macrophages, cells were
removed from the wells at day 7 using Cell Dissoci-
ation Buffer (Gibco,Thermo Fisher) and a pastette.
Cells were resuspended in PEA buffer and counted,
then approximately 106 cells per test were stained for
flow cytometry.
Leukapheresis-derived macrophages were removed
from the culture bags at day 7 using PBS/EDTA buffer
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(CliniMACS buffer, Miltenyi) containing pharma-
ceutical grade 0.5% human albumin from serum
(HAS; Alburex). Harvested cells were resuspended in
excipient composed of two licensed products: 0.9%
saline for infusion (Baxter) with 0.5% human albumin
(Alburex).
Flow cytometry characterization
Monocyte and macrophage cell surface marker ex-
pression was analyzed using either a FACSCanto II
(BD Biosciences) or MACSQuant 10 (Miltenyi) flow
cytometer. Approximately 20 000 events were ac-
quired for each sample. Cell surface expression of
leukocyte markers in freshly isolated and day 7 matured
cells was carried out by incubating cells with specific
antibodies (final dilution 1:100). Cells were incubated
for 5 min with FcR block (Miltenyi) then incubated
at 4°C for 20 min with antibody cocktails. Cells were
washed in PEA, and dead cell exclusion dye DRAQ7
(BioLegend) was added at 1:100.
Cells were stained for a range of surface markers
as follows: CD45-VioBlue, CD14-PE or CD14-PerCP-
Vio700, CD163-FITC, CD169-PE and CD16-APC
(all Miltenyi), CCR2-BV421, CD206-FITC, CXCR4-
PE and CD115-APC (all BioLegend), and 25F9-
APC and CD115-APC (eBioscience). Both monocytes
and macrophages were gated to exclude debris, dou-
blets and dead cells using forward and side scatter and
DRAQ7 dead cell discriminator (BioLegend) and ana-
lyzed using FlowJo software (Tree Star).
From the initial detailed phenotyping, a panel
was developed as Release Criteria (CD45-VB/CD206-
FITC/CD14-PE/25F9-APC/DRAQ7) that defined the
development of a functional macrophage from mono-
cytes. Macrophages were determined as having mean
fluorescence intensity (MFI) five times higher than the
level on day 0 monocytes for both 25F9 and CD206.
A second panel was developed which assessed other
markers as part of an Extended Panel, composed of
CCR2-BV421/CD163-FITC/CD169-PE/CD14-
PerCP-Vio700/CD16-APC/DRAQ7), but was not used
as part of the Release Criteria for the cell product.
Functional characterization
Both monocytes and macrophages from buffy coat
CD14 cells were tested for phagocytic uptake using
pHRodo beads, which fluoresce only when taken into
acidic endosomes. Briefly, monocytes or macrophages
were cultured with 1–2 uL of pHRodo Escherichia coli
bioparticles (LifeTechnologies,Thermo Fisher) for 1 h,
then the medium was taken off and cells washed to
remove non-phagocytosed particles. Phagocytosis was
assessed using an EVOS microscope (Thermo Fisher),
images captured and cellular uptake of beads quantified
using ImageJ software (NIH freeware, https://imagej
.nih.gov/ij).
The capacity to polarize toward defined differen-
tiated macrophages was examined by treating day 7
macrophages with interferon (IFN)-γ (50 ng/mL) or
interleukin (IL)-4 (20 ng/mL) for 48 h to induce po-
larization to M1 or M2 phenotype (or M[IFNγ] versus
M[IL-4], respectively). After 48 h, the cells were vi-
sualized by EVOS bright-field microscopy, then
harvested and phenotyped as before.
Further analysis was performed on the cytokine and
growth factor secretion profile of macrophages after
generation and in response to inflammatory stimuli.
Macrophages were generated from healthy donor buffy
coats as before, and either left untreated or stimu-
lated with tumor necrosis factor (TNF)-α (50 ng/mL,
Peprotech) and polyinosinic:polycytidylic acid (poly I:C,
a viral homolog which bindsTLR3, 1 µg/mL, Sigma)
to mimic the conditions present in the inflamed liver,
or lipopolysaccharide (LPS, 100 ng/mL, Sigma) plus
IFN-γ (50 IU/mL, Peprotech) to produce a maximal
macrophage activation. Day 7 macrophages were in-
cubated overnight and supernatants collected and spun
down to remove debris, then stored at −80°C until
testing. Secretome analysis was performed using a 27-
plex human cytokine kit and a 9-plex matrix
metalloprotease kit run on aMagpix multiplex enzyme-
linked immunoassay plate reader (BioRad).
Product stability
Various excipients were tested during process devel-
opment including PBS/EDTA buffer; PBS/EDTA
buffer with 0.5% HAS (Alburex), 0.9% saline alone
or saline with 0.5% HAS. The 0.9% saline (Baxter)
with 0.5% HAS excipient was found to maintain
optimal cell viability and phenotype (data not shown).
The stability of the macrophages from cirrhotic donors
after harvest was investigated in three process opti-
mization runs, and a more limited range of time points
assessed in the process validation runs (n = 3). After
harvest and re-suspension in excipient (0.9% saline
for infusion, 0.5% human serum albumin), the bags
were stored at ambient temperature (21–22°C) and
samples taken at 0, 2, 4, 6, 8, 12, 24, 30 and 48 h post-
harvest. The release criteria antibody panel was run
on each sample, and viability and mean fold change
from day 0 was measured from geometric MFI of 25F9
and CD206.
Statistical analysis
Results are expressed as mean ± SD.The statistical sig-
nificance of differences was assessed where possible
with the unpaired two-tailed t-test using GraphPad
Prism 6. Results were considered statistically signif-
icant when the P value was <0.05.
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Results
In this study, we have defined a number of aspects of
the cultured macrophage, modeling first with healthy
donor samples to carry out extensive preclinical char-
acterization of normal macrophages.This knowledge
has then been applied to full-scale leukapheresis col-
lections from patients with liver cirrhosis to optimize
and validate the final cell therapy manufacturing
procedure.
Optimizing GMP-compliant culture of monocytes
The sorting efficiency using CD14 CliniMACS beads
was extremely high, and results were comparable
across all methods, whether the cells were sourced from
buffy coat or leukapheresis from cirrhotic patients;
bead-labeled cells were manually labeled and isolated
over LS columns or processed using the completely au-
tomated CliniMACS prodigy system. Flow cytometric
analysis of the pre-sort and positive and negative frac-
tions indicated that from an initial mean of 20.5%
monocytes, the positive fraction was highly enriched
(95.9%), with minimal loss in the negative fraction
(4.1%) from 26 normal donor isolates using CliniMACS
CD14 reagents and LS columns (Figure 1A). Very
similar figures were seen in cirrhotic donor samples sepa-
rated using the CliniMACS Prodigy (Figure 1B),
although cirrhotic donors had a higher (although not
significant) initial mean percentage of monocytes in their
collections (Figure 1C).We have previously reported
the manufacture of macrophages in AIM-V complete
culture medium.However, the antibiotic content of this
Figure 1. Initial optimization of GMP macrophage culture from normal donors. (A) CliniMACS CD14 bead isolation of monocytes using
LS columns generated highly purified CD14 fractions (n = 26). (B) CliniMACS Prodigy CD14 selection produced equally highly en-
riched CD14+ fractions from apheresis collection from cirrhotic volunteers. (C) Cirrhotic patients showed a trend to higher CD14 numbers
in peripheral blood (n = 11, P = 0.108). (D) Although not significant,TexMACS produced the highest and most consistent yield of mac-
rophages (n = 6–10). (E) Macrophages fromTexMACS culture were also significantly larger in size than those cultured in AIM-V medium
(P < 0.0001, n = 5). (F) The GMP-grade M-CSF from research and development generated a similar yield of macrophages to standard
M-CSF but with stronger expression of macrophage marker 25F9 (n = 6). (G) Microscopic imaging indicates that DMEM + 5% AB pro-
duced clumping and sticking in macrophage cultures, unlike those generated in defined media.
ARTICLE IN PRESS
Macrophages as an advanced cellular therapeutic 5
medium was not compatible with the testing of product
sterility by assessment of bacterial growth and therefore
we evaluated the antibiotic-free TexMACS complete
medium as a comparator. GMP-grade TexMACS
culture medium demonstrated a consistently higher con-
version rate to macrophages compared with AIM-V,
although this did not reach statistical significance
(Figure 1D). Culture in DMEM plus 5% AB serum
also resulted in a comparable rate of macrophage con-
version; however, DMEM cultured macrophages were
also strongly adherent to the substrate, which re-
sulted in cell loss during harvesting (Figure 1G). In
addition, monocytes cultured inTexMACS produced
significantly larger macrophages as calculated using
forward scatter from flow cytometry (Figure 1E). Initial
development experiments used a premium research
grade M-CSF (Miltenyi) to supplement the culture
medium. This was compared with a GMP-grade
M-CSF (R&DSystems), both used at 100 ng/mL.There
were no significant differences in morphology or mac-
rophage yield when culturing with either source, but
higher expression of the macrophage marker 25F9 was
seen in macrophages generated with GMP-grade
M-CSF (Figure 1F). Therefore, we considered
TexMACS medium (Miltenyi) supplemented with
GMP-grade M-CSF (R&D Systems) to be the optimal
medium for the production of GMP grademacrophages.
Derivation of macrophages from frozen monocytes
For therapeutic use, freezing aliquots of monocytes
to generate multiple macrophage doses would be at-
tractive.We assessed whether there were any significant
differences in macrophage yield or phenotype that
would preclude the use of frozen stocks. Our data in-
dicated that there were differences in both yield and
in phenotype. In particular, there were significant drops
in the expression of CD206 and CD163 (Figure 2).
There was also a converse increase in CCR2 expression
(Figure 2).This would suggest that the macrophages
from frozen monocytes develop a more M1-like, clas-
sically activated phenotype. Additionally, the mean
viability of macrophages from thawed monocytes
was significantly lower than from fresh monocytes in
these experiments (viability 45.5% versus 75.2% in
fresh macrophages, n = 4–6, P = 0.0098). It was con-
cluded that the poor viability (and therefore yields)
and less advantageous phenotype precluded the further
development of the macrophage product from frozen
cells for initial clinical use.
Extended functional analysis: healthy donor
macrophages
Functional characterization of normal macrophages
investigated the capacity of the cells to take up par-
ticles. Using pHRodo beads in these studies gives an
accurate assessment because the beads are clear until
phagocytosed and fluoresce once exposed to the acidic
environment of the phagolysosome. Phagocytosis was
quantified from EVOS images (Figure 3A), assess-
ing total cell numbers per field, total cells containing
fluorescent beads, and then number of beads per cell.
Quantification of phagocytosis using this method dem-
onstrated that there was no difference in uptake
between monocytes and macrophages (Figure 3B).
Further analysis indicated that stimulation of mac-
rophages withTNF-α and poly I:C had no significant
effect on phagocytosis (data not shown).
Our phenotype analysis indicated that the mac-
rophages at harvest are not polarized, but they do
demonstrate high CD206 and CD169 expression char-
acteristic of alternatively activated macrophages
(Figure 6).We used IFN-γ and IL-4 stimulation to de-
termine whether the macrophages at harvest were
capable of responding to polarizing cytokine exposure.
At day 2 of polarization, there was a morphological dif-
ference in the cultures, with IFN-γ–treated macrophages
Figure 2. Phenotyping of fresh versus frozen monocytes for GMP macrophages. Buffy coat monocytes were isolated, an aliquot frozen
and stored in LN2 and the remainder used to generate macrophages. After thawing, monocytes were cultured to macrophages and phe-
notype compared.Although many markers are unchanged in macrophages made from thawed monocytes, CD206 and CD163 are significantly
reduced and CCR2 significantly increased in macrophages from frozen monocytes (n = 10).
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showing rounded, angular shape (Figure 4A), whereas
IL-4–treatedmacrophages showed characteristic spindle-
shaped morphology [25]. Although there was no
significant difference in the 25F9 marker expression
between the cultures, the IL-4–treated cells were able
to significantly up-regulate CD206, characteristic of po-
larizedM2a macrophages (Figure 4B).This polarization
is characteristic of macrophages in vitro and does not
necessarily predict functional capacity in recipients.
A final aspect of cell product assessment was de-
termination of macrophage factor secretion profile
at rest and after stimulation (Figure 5). Macrophages
expressed low levels of IL-1Ra, IL-10 and vascular en-
dothelial growth factor (VEGF) at rest. Stimulation
with TNF-α and poly I:C was used to mimic an in-
flamed environment and led to significant increases
in production of the pro-regenerative/anti-inflammatory
factors VEGF, IL-10 and IL-1Ra, but no increase in
IL-12. IL-10 expression was not increased strongly by
LPS/IFN-γ stimulation, but conversely IL-12 expres-
sion was strongly increased by LPS/IFN-γ.
TNF-α/poly I:C stimulation increased expres-
sion of CCL3, 4 and 5 but with no significant increase
in CCL2 (supplementary Figure S1). Macrophages
constitutively expressed high levels of MMP 7, 9 and
12 with low expression of MMP3. This MMP ex-
pression was not modulated significantly after
stimulation (supplementary Figure S2) or polariza-
tion, and there was negligible expression of MMPs 1,
7, 8, 10 and 11 (data not shown).
Process validation: cirrhotic patients
The cell culture and identity data were used to design
the GMP process, which was then validated. A set of
markers was chosen from the broad phenotyping panel
to use as product Release Criteria inclusive of cell iden-
tity and functional markers.These were expression of
Figure 3. Phagocytosis of monocytes and macrophages. (A) EVOS image of bright-field/fluorescein isothiocyanate fluorescence indicating
pHRodo bead uptake (magnification ×100). (B) Quantification of uptake indicates that there is no significant difference in uptake of beads
by monocytes or macrophages, and no difference in number of beads that were taken up (n = 4). Data are expressed as mean ± SD.
Figure 4. Microscopic and phenotypic changes in polarized mac-
rophages. (A) EVOS bright-field image of polarized macrophages
shows distinct differences in morphology, with angular, spiky
M1/M(IFNγ) and elongated smooth spindle-shaped M2/M(IL-4)
macrophages (magnification ×400). (B) Flow cytometric analysis
shows no significant difference in macrophage marker 25F9 in all,
but IL-4 stimulated macrophages significantly increase their CD206
expression, but decreased in IFN-γ treated macrophages (n = 5,
mean ± SD, P < 0.05).
ARTICLE IN PRESS
Macrophages as an advanced cellular therapeutic 7
CD45 and CD14 for lineage determination and 25F9
as a marker of macrophage maturity. In addition,
CD206 was chosen as a surrogate marker for phago-
cytosis and scavenging capacity, which would effectively
identify the development of suitable functional mac-
rophages.The viability stain DRAQ7 was included as
a final component of the GMP Release Criteria panel.
For further information on the cell product, we used
a second phenotyping set, termed the Extended Panel,
which assesses expression of CD163, CD169 and
CCR2.This panel was validated on leukapheresis do-
nations from seven cirrhotic volunteers. CD14+ cells
were selected using the CliniMACS Prodigy device,
and the cells were cultured as described earlier in the
article. The levels of expression of each marker are
shown on day 0 enriched monocytes and correspond-
ing day 7 macrophages in Figure 6. Differentiated
cells retain CD45+ CD14+ expression and 25F9,
CD206, CD169 and CD163 was significantly elevated
in macrophages. CCR2 becomes significantly down-
regulated in macrophages compared with monocytes.
We also assessed migratory capacity of the mac-
rophages post-harvest using trans-well chemotaxis assay
and confirmed that they retained the ability to migrate
to suitable targets in vitro despite the down-regulation
of CCR2 (data not shown).
Stability studies were performed on macrophages
stored at controlled room temperature (21–22°C) in
optimal excipient, as determined during process op-
timization (clinical grade 0.9% saline with 0.5% HAS).
After sampling at each time point, the cells were as-
sessed for phenotype and viability. Data from all three
process optimization runs indicated that both cell vi-
ability and phenotype (25F9/CD206 MFI) were
maintained to 48 h post-harvest (Figure 7), indicat-
ing that the process reproducibly produces a very stable
cell product. Release Criteria were thus established
that the macrophages should be CD45/CD14 posi-
tive, with a viability greater than 80%, and have a MFI
for 25F9 and CD206 more than fivefold higher than
the MFI of the original monocytes at day 0. All final
results for Release Criteria process validation includ-
ing stability are detailed in Table I.
Discussion
Macrophages derived from CD14+ monocytes sourced
from peripheral blood or leukapheresis can reverse ex-
perimental liver fibrosis [11,23,26]. In contrast,
undifferentiated CD14+ monocytes can exacerbate liver
disease, as shown by CCR2-mediated blockade of
monocyte recruitment in models of liver disease [27].
In our previous study, we showed that equivalent
cells can be generated from healthy blood donors and
cirrhotic patients [23]. In this study, we show that mac-
rophages can be generated in xeno-free, fully GMP-
compliant conditions at a scale of multiples of 108 cells
and rigorously validated for use in a first-in-human
clinical trial. Throughout the current study, we have
determined the criteria of reproducibility and function
Figure 5. Secretome analysis of healthy donor macrophages. Day
7 macrophages (n = 3) were untreated or stimulated for 12 h with
TNF-α and poly I:C (PIC) or IFN-γ and LPS, then analyzed by
BioRad multiplex enzyme-linked immunoassay. Both IL-10 (A) and
IL-1Ra (B) were significantly up-regulated byTNF-α/PIC, as was
VEGF (D). The IL-12p40 level (C) was not affected by TNF-α/
PIC but was significantly increased by LPS/IFN-g. Data are
expressed as mean + SD, *P < 0.05.
Figure 6. Phenotype panels for clinical grade macrophages taken
from cirrhotic patients (n = 7). (A) Release criteria showing MFI
increase between day 0 monocytes and day 7 macrophages. (B) Ex-
tended panel including two further scavenger receptors (CD163/
CD169) plus a marker for macrophage migration. Note that a single
outlier on the CCR2 day 7 data was excluded from analysis after
Grubb’s test (●). Data are presented as mean ± SD, P < 0.05.
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of the macrophages using healthy donor cells and then
applied these to cells from cirrhotic volunteer donors
to establish and validate the manufacturing proce-
dure for clinical use.
In this study and our previous feasibility study [23],
we have used CD14 microbead selection to isolate
monocytes as a manufacturing raw material because
this technique has been shown to give high yields of
pure monocytes, suitable for further manufacturing
[14]. CD14 selection has no appreciable adverse effect
on function such as response toTLR ligation or CD40
ligation [28] and yielded cells efficient at reversing cir-
rhosis in experimental models [23].The CliniMACS
Plus device has been widely used for isolation for
CD14+ monocytes, principally for the preparation of
monocyte-derived dendritic cells [13,29]. Although ef-
fective, this methodology involves a series of manual
washes and incubations, which can reduce overall cell
yield. In this study, we report the first use of the
CliniMACS Prodigy device to automate large parts
Figure 7. Stability of GMP cirrhotic patient macrophages. (A) Viability shows no significant decrease even after 48 h at ambient temper-
ature. (B) Expression of 25F9 decreases steadily over time but even at 48 h remains well above the fivefold increase required for validity.
(C) CD206 remains high until approximately 24–30 h after harvest then drops more rapidly, but also remains well above the fivefold thresh-
old established for the trial criteria (n = 3).
Table I. Data from process validation runs 1–3.
Acceptance criteria Expected result
Actual result
Patient 1 Patient 2 Patient 3
Selection (D0)
CD14 yield
≥40% 41% 59% 64%
Final macrophage yield
(viable cell number)
1 × 107 to 1 × 109 5.11 × 108 5.73 × 108 2.9 × 108
Harvest (D7)
Macrophage viability
≥80% 87% 95% 87%
Harvest (D7)
25F9 MFI fold increase
≥5 17 19 26
Harvest (D7)
CD206 MFI fold increase
≥5 33 28 82
Stability (48 h)
MacrophageViability
≥80% 91% 88% 86%
Stability (48 h)
25F9 MFI fold increase
≥5 18 8 11
Stability (48 h)
CD206 MFI fold increase
≥5 21 19 41
Details include the parameters that will be used as release criteria for final product.
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of the CD14+ isolation process, with only a single final
wash of harvested cells to remove buffer before cell
culture.We were easily able to replicate our transla-
tion yields of monocytes using small-scale selection
over MACS LS columns to the CliniMACS Prodigy,
with identically high levels of CD14+ enrichment using
both methods.The automated procedure shortens pro-
cessing time, reduces the amount of manual handling
and led to average yields of many multiples of 108
CD14+ cells.This therefore makes it feasible to man-
ufacture macrophage products at significant scale, with
fewer manual handling steps. It is worth noting that
cirrhotic donors have high numbers of circulating
monocytes, commonly more than 30% of the Total
Nucleated Cells, which is considerably more than re-
ported values for healthy donors or the patients
donating for CD14 processing [13,29].Very high start-
ing numbers of target cells can potentially reduce
overall selection efficiency due to overwhelming the
capacity of reagent and selection columns. Despite the
high monocyte numbers in cirrhotic patients, the
CliniMACS Prodigy system was able to reproduc-
ibly isolate sufficient cells to meet our manufacturing
criteria of a yield of at least 40% CD14+ cells.
We have previously reported that this process could
be carried out using GMP-compatible reagents in-
cluding human donor serum and carrier-free cytokines.
Here we have further adapted the process to eradi-
cate serum entirely and used only growth factor–
supplemented GMP-standard defined culture medium
with identical yield to serum-supplemented medium.
In addition to the anticipated increased manufactur-
ing reproducibility of using defined medium, we found
that harvesting macrophages was more efficient with
the eradication of donor serum from the cell culture
because the final product is more loosely adherent to
the bag. This is of considerable benefit in minimiz-
ing cell loss during harvest of CD14-derived cell
products. With the increasing availability of GMP-
grade cytokines, we were also able to validate our
method using GMP-grade M-CSF with no detri-
ment to final cell yield or phenotype.The higher mean
fluorescence levels of the macrophage marker 25F9
on cells cultured in GMP-grade cytokine were of prac-
tical benefit in determining fold-change over baseline
as a release criterion by flow cytometry.
We have validated flow cytometry as the principal
functional ReleaseCriteria for themacrophage product.
This was used as a single platform to analyze the product
pre-release, including absolute cell counting (TruCount)
and viability (exclusion of DRAQ7). In a product such
as this, where differentiation from a precursor to a final
phenotype is the aim of the manufacturing process,
the use of fold change of the whole population MFI
was felt to be more relevant than use of arbitrary per-
centage positivity on the basis of quadrant gating.We
were able to generate robust limits for the increase in
25F9 to define the macrophage identity, plus expres-
sion of the phagocytosis-associated marker CD206 as
the minimum release criteria. Of note, it was not pos-
sible to establish a bead phagocytosis assay to define
a macrophage phenotype that differed from undiffer-
entiatedmonocytes because both performed identically
in this assay.The use of acid phagosome–activated flu-
orescent beads increased the accuracy of this assay
because only internalized beads, and not surface-bound
beads, were quantified. However, CD206, CD169
and CD163 expression was definitively confined to
macrophages and the former adopted as a surrogate
marker of phagocytic function for product release in
the trial.
In the MATCH trial, provided that dose escala-
tion is successfully completed, the main treatment
arm will consist of three infusions on a monthly basis
of the maximum tolerated dose of macrophages.
This treatment regime will consist of multiples of
108 macrophages per dose. For convenience, this
would ideally have been delivered through a single
leukapheresis collection, followed by selection and
cryopreservation of CD14+ cells, then manufacture of
three products from thawed monocytes. However,
the data we generated in this study did not support
this manufacturing strategy because macrophage
yield per input CD14+ cells was only about 40%,
which is insufficient to generate multiple doses of up
to109 macrophages.The phenotype of the macrophages
after differentiation from cryopreserved CD14 cells
was also altered with significant drops in the expression
of CD206 and CD163 compared with fresh product.
There was also a converse increase in CCR2 expres-
sion, a chemokine receptor associated with trafficking
to inflamed sites, highly expressed on steady state and
inflammatory monocytes and associated potential ex-
acerbation of disease [7]. All of these factors meant
that thawed CD14-derived macrophages did not meet
our manufacturing criteria. It is likely that specialist
cryopreservation strategies will be needed to support
better yield and function of thawed monocytes [30].
Having defined ourmethods and assays for themac-
rophage product, we were able to use this to perform
extended analysis on themacrophages, validate the full-
scale manufacturing process and establish product
stability. Our extended analysis indicated that mac-
rophages generated by this xeno-free process had both
a pro-regenerative phenotype and weremigration com-
petent. The cells stably expressed a variety of MMP
and CC chemokines, known to be associated with the
in vivo regenerative function of macrophages in liver
fibrosis [5,11,23]. Increases in the production of anti-
inflammatory cytokines IL-10 and IL-1Ra and the pro-
angiogenic factor VEGF, but not IL-12 from the
macrophages in response toTNF-driven inflammation
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signals, also confirmed the anti-inflammatory pheno-
type [31].The cells retained a degree of plasticity, with
their expression of the scavenger molecule CD206
considerably up-regulated by incubation with IL-4 but
slightly decreased by incubation with IFN-γ. This
polarization competence was demonstrated on cul-
turedmacrophages but has not been confirmed in vivo.
However, phenotype and cytokine profiles in re-
sponse to inflammatory factors present in inflamed liver
leads us to conclude that the transfused macrophages
will contribute to damage resolution rather than ex-
acerbate pathology.
Final manufacturing process validation runs were
successfully carried out, and we were able to manu-
facture a minimum of 2.9 × 108 and maximum of
5.7 × 108 macrophages from cirrhotic volunteers.More-
over, the product proved to be extremely stable for
up to 48 h in excipient at controlled room tempera-
ture. This stability will allow significant flexibility in
scheduling infusion of the macrophages to patients and
could be used to underpin the use of the product in
multiple centers. These validation and stability data
were used to prepare the relevant validation docu-
mentation for submission to the Medicines and
Healthcare Products Regulatory Agency as part of the
Investigational Medicinal Product Dossier and a Clin-
ical Trial Authorisation was subsequently issued for
the MATCH trial.
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